Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2008 2
2009 4
2010 12
2011 10
2012 6
2015 1
2017 5
2018 10
2019 7
2020 2
2021 3
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

53 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
Niisato Y, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Shimada Y. Niisato Y, et al. Among authors: hatachi y. Anticancer Res. 2021 Apr;41(4):2203-2207. doi: 10.21873/anticanres.14996. Anticancer Res. 2021. PMID: 33813435
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
Moriwaki T, Nishina T, Sakai Y, Yamamoto Y, Shimada M, Ishida H, Amagai K, Sato M, Endo S, Negoro Y, Kuramochi H, Denda T, Hatachi Y, Ikezawa K, Nakajima G, Bando Y, Tsuji A, Yamamoto Y, Morimoto M, Kobayashi K, Hyodo I. Moriwaki T, et al. Among authors: hatachi y. Jpn J Clin Oncol. 2022 Jul 8;52(7):725-734. doi: 10.1093/jjco/hyac073. Jpn J Clin Oncol. 2022. PMID: 35470391 Clinical Trial.
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment.
Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Negoro Y, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okuyama H, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Moriwaki T. Nakajima H, et al. Among authors: hatachi y. Front Oncol. 2021 Jun 15;11:688709. doi: 10.3389/fonc.2021.688709. eCollection 2021. Front Oncol. 2021. PMID: 34211856 Free PMC article.
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS).
Chida K, Kotani D, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okita Y, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Shimada Y. Chida K, et al. Among authors: hatachi y. Front Oncol. 2021 Mar 8;11:576036. doi: 10.3389/fonc.2021.576036. eCollection 2021. Front Oncol. 2021. PMID: 33763345 Free PMC article.
53 results